Ads
related to: sanofi- Astellas Pharma Support
Learn about our Support Solutions
and find helpful enrollment forms.
- Patient Commitment
Our Patient Centricity Team aims to
change the course of cancer care.
- Science and Innovation
View our approach to finding
solutions for cancer's complexities
- World-Class Products
Discover more about our FDA-
approved treatment options.
- Astellas Pharma Support
Search results
Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
Bloomberg via Yahoo Finance· 3 days ago(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its...
Analyst Report: Sanofi
Morningstar Research via Yahoo Finance· 20 hours agoSanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's ...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 14 hours agoThe first-quarter 2024 earnings season picked up pace this week, with Merck MRK, Sanofi SNY,...
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 day agoImage source: The Motley Fool. Sanofi (NASDAQ: SNY) Q1 2024 Earnings Call Apr 25, 2024, 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers...
Sanofi crosses Sjögren’s off $5B drug’s hit list after phase 2 data disappoint
FierceBiotech· 2 days agoSanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product”...
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks via Yahoo Finance· 2 days agoSanofi SNY reported first-quarter 2024 adjusted earnings of 96 cents per American depositary share,...
Q2 2024 EPS Estimates for Sanofi (NASDAQ:SNY) Cut by Leerink Partnrs
ETF DAILY NEWS· 6 days agoSanofi (NASDAQ:SNY – Free Report) – Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for Sanofi in a research report issued to clients ...
Sanofi Sales, Profit Beat Expectations
The Wall Street Journal· 2 days agoSanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength...
Sanofi wins in late-stage trial for blood disorder candidate (NASDAQ:SNY)
Seeking Alpha· 4 days agoSanofi's (SNY) oral therapy, rilzabrutinib, shows promise in a Phase 3 trial for an autoimmune blood...
Sanofi profit slips on generic competition and currency effects
Reuters via Yahoo Finance· 2 days ago(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap...
